Kahn Brothers Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.2M Sell
464,001
-20,732
-4% -$542K 1.77% 15
2026
Q1
$13.6M Sell
484,733
-69,217
-12% -$1.84M 2.41% 14
2025
Q4
$13.8M Sell
553,950
-153,194
-22% -$3.86M 2.44% 11
2025
Q3
$18M Sell
707,144
-23,845
-3% -$589K 3.39% 11
2025
Q2
$17.7M Sell
730,989
-4,200
-0.6% -$97.9K 3.56% 12
2025
Q1
$18.6M Sell
735,189
-25,901
-3% -$678K 3.77% 12
2024
Q4
$20.2M Sell
761,090
-235,935
-24% -$6.4M 4.39% 12
2024
Q3
$28.9M Sell
997,025
-5,405
-0.5% -$158K 4.97% 10
2024
Q2
$28M Sell
1,002,430
-20,289
-2% -$559K 4.71% 11
2024
Q1
$28.4M Sell
1,022,719
-2,962
-0.3% -$82.2K 4.21% 10
2023
Q4
$29.5M Sell
1,025,681
-30,078
-3% -$909K 4.65% 12
2023
Q3
$35M Sell
1,055,759
-10,332
-1% -$365K 5.46% 10
2023
Q2
$39.1M Buy
1,066,091
+36,429
+4% +$1.42M 5.73% 10
2023
Q1
$42M Sell
1,029,662
-8,644
-0.8% -$373K 6.05% 10
2022
Q4
$53.2M Sell
1,038,306
-4,047
-0.4% -$194K 7% 7
2022
Q3
$45.6M Sell
1,042,353
-5,146
-0.5% -$250K 7.11% 8
2022
Q2
$54.9M Buy
1,047,499
+5,517
+0.5% +$281K 7.39% 8
2022
Q1
$53.9M Buy
1,041,982
+24,054
+2% +$1.25M 6.85% 8
2021
Q4
$60.1M Buy
1,017,928
+36,940
+4% +$1.83M 8.26% 4
2021
Q3
$42.2M Buy
980,988
+156,484
+19% +$6.93M 5.94% 10
2021
Q2
$32.3M Buy
824,504
+162,217
+24% +$6.31M 4.62% 11
2021
Q1
$24M Sell
662,287
-12,431
-2% -$441K 3.71% 12
2020
Q4
$24.8M Sell
674,718
-55,223
-8% -$2.03M 4.33% 13
2020
Q3
$25.4M Sell
729,941
-75,859
-9% -$2.66M 4.82% 11
2020
Q2
$25M Sell
805,800
-6,113
-0.8% -$208K 4.22% 11
2020
Q1
$25.1M Sell
811,913
-41,599
-5% -$1.42M 4.6% 10
2019
Q4
$31.7M Sell
853,512
-2,111
-0.2% -$75.2K 3.85% 11
2019
Q3
$29.2M Buy
855,623
+6,082
+0.7% +$221K 3.66% 11
2019
Q2
$34.9M Buy
849,541
+287,138
+51% +$11.4M 4.37% 11
2019
Q1
$22.7M Sell
562,403
-864
-0.2% -$34.6K 3.54% 12
2018
Q4
$23.3M Sell
563,267
-3,057
-0.5% -$127K 4.21% 11
2018
Q3
$23.7M Sell
566,324
-10,179
-2% -$392K 3.64% 12
2018
Q2
$19.8M Sell
576,503
-3,138
-0.5% -$107K 3.16% 15
2018
Q1
$19.5M Sell
579,641
-4,914
-0.8% -$169K 3.11% 15
2017
Q4
$20.1M Sell
584,555
-3,045
-0.5% -$104K 3.16% 16
2017
Q3
$19.9M Sell
587,600
-21,207
-3% -$682K 3.04% 15
2017
Q2
$19.4M Sell
608,807
-94,878
-13% -$2.99M 2.96% 14
2017
Q1
$22.8M Sell
703,685
-203,061
-22% -$6.4M 3.93% 11
2016
Q4
$27.9M Sell
906,746
-62,678
-6% -$1.91M 4.72% 11
2016
Q3
$31.2M Sell
969,424
-249,913
-20% -$8.36M 5.64% 9
2016
Q2
$40.7M Sell
1,219,337
-301,103
-20% -$9.61M 7.89% 6
2016
Q1
$42.8M Sell
1,520,440
-134,206
-8% -$3.83M 8.01% 6
2015
Q4
$50.7M Sell
1,654,646
-106,629
-6% -$3.35M 9.05% 5
2015
Q3
$52.5M Sell
1,761,275
-109,443
-6% -$3.51M 9.72% 3
2015
Q2
$59.5M Sell
1,870,718
-38,093
-2% -$1.24M 10.03% 2
2015
Q1
$63M Sell
1,908,811
-76,100
-4% -$2.42M 10.64% 1
2014
Q4
$58.7M Sell
1,984,911
-107,449
-5% -$3.08M 10.11% 3
2014
Q3
$58.7M Sell
2,092,360
-146,851
-7% -$4.12M 9.55% 3
2014
Q2
$62.2M Buy
2,239,211
+12,300
+0.6% +$351K 9.04% 4
2014
Q1
$67.9M Buy
2,226,911
+224,565
+11% +$6.7M 9.69% 2
2013
Q4
$58.2M Sell
2,002,346
-641,088
-24% -$18.7M 10.01% 2
2013
Q3
$72M Sell
2,643,434
-35,436
-1% -$964K 10.48% 1
2013
Q2
$71.2M Buy
+2,678,870
New +$74M 10.99% 1

Other funds holding PFE

Kahn Brothers Group's PFE Position: Q2 2026 in Review

Kahn Brothers Group reduced its Pfizer (PFE) stake by 4.3% in Q2 2026, selling an estimated $542K and leaving 464,001 shares worth $11.2M. The position accounts for 1.77% of the portfolio, ranked #15.

Kahn Brothers Group first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $72M in Q3 2013. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Kahn Brothers Group held 464,001 shares of Pfizer worth $11.2M as of Q2 2026.
  • Kahn Brothers Group sold 20,732 Pfizer shares in Q2 2026, an estimated $542K.
  • Pfizer made up 1.77% of Kahn Brothers Group's portfolio in Q2 2026, its #15 holding.
  • Kahn Brothers Group first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Kahn Brothers Group's Pfizer position peaked at $72M in Q3 2013.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Kahn Brothers Group's 13F filing for Q2 2026, filed 14 Aug 2026.